About VeraDermics
VeraDermics is a company based in San Antonio (United States) founded in 2020 by Kyle Ryder. VeraDermics has raised $262.71 million across 5 funding rounds from investors including Marshall Wace, Citadel and Columbia Threadneedle Investments. VeraDermics offers products and services including VDPHL and Dermatology Pipeline. VeraDermics operates in a competitive market with competitors including Ironwood Pharma, scPharmaceuticals, Crossject, Valeritas and CeQur, among others.
- Headquarter San Antonio, United States
- Founders Kyle Ryder
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Veradermics, Incorporated
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$262.71 M (USD)
in 5 rounds
-
Latest Funding Round
$150 M (USD), Series C
Oct 16, 2025
-
Investors
Marshall Wace
& 16 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of VeraDermics
VeraDermics is a publicly listed company on the NYSE with ticker symbol MANE in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of VeraDermics
VeraDermics offers a comprehensive portfolio of products and services, including VDPHL and Dermatology Pipeline.
Once-daily oral treatment for pattern hair loss.
Novel therapeutics for conditions like warts and atopic dermatitis.
People of VeraDermics
Unlock access to complete
Funding Insights of VeraDermics
VeraDermics has successfully raised a total of $262.71M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $150 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in VeraDermics
VeraDermics has secured backing from 17 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Marshall Wace, Citadel and Columbia Threadneedle Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity firm focused on life science sector
|
Locked | Locked | Locked | |
|
Early- to growth-stage startups are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
PhiFund Ventures is focused on early-stage life sciences investments.
|
Locked | Locked | Locked |
Investor details for VeraDermics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by VeraDermics
Investment portfolio details for VeraDermics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - VeraDermics
Detailed financials for VeraDermics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Veradermics Comparisons
Peer comparison for VeraDermics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of VeraDermics
VeraDermics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ironwood Pharma, scPharmaceuticals, Crossject, Valeritas and CeQur, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for gastrointestinal disorders, including linaclotide, are developed.
|
|
| Locked | Locked | Locked |
Provider of a device for subcutaneous drug delivery for the treatment of bacterial infections and heart failure
|
|
| Locked | Locked | Locked |
Needle-free self-injectable drugs
|
|
| Locked | Locked | Locked |
Wearable insulin patch pumps are developed for transdermal delivery.
|
|
| Locked | Locked | Locked |
Wearable insulin delivery patches are developed for mealtime dosing.
|
|
| Locked | Locked | Locked |
Developer of vaccines to treat cancer and infectious diseases
|
Detailed competitors of VeraDermics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Veradermics
Complete news archive for VeraDermics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about VeraDermics
VeraDermics was founded in 2020.
VeraDermics is headquartered in San Antonio, United States. It is registered at San Antonio, Texas, United States.
VeraDermics is a funded company, having raised a total of $262.71M across 5 funding rounds to date.
VeraDermics was founded in 2020 and is based in San Antonio, United States. Operations focus on the biotechnology sector, where drug-delivery solutions for pediatric dermatological conditions, particularly warts, are developed. The proprietary WartPatch serves as a targeted platform for administering treatments to children, addressing common skin issues in this demographic. Activities emphasize safe and effective delivery mechanisms for young patients.
VeraDermics's top competitors include Ironwood Pharma, scPharmaceuticals and Crossject.
VeraDermics offers VDPHL and Dermatology Pipeline.
Yes, VeraDermics is publicly traded on NYSE under the ticker symbol MANE.
VeraDermics has 17 investors. Key investors include Marshall Wace, Citadel, Columbia Threadneedle Investments, Suvretta Capital Management, and Longitude Capital.
The ticker symbol of VeraDermics is MANE on NYSE.